Payment overview · 2025
General Payments
$1,796.18
32 reported records · 9 companies
Healthcare provider profile · identity verified
Khoa D Tran, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · ERIE, PA · NPI 1427013986
Verified facts
What the public records show
CMS Open Payments records show Khoa D Tran, MD received $1,796.18 in general payments during 2025 across 32 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Invega Sustenna, Uzedy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Vraylar by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Invega Sustenna by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 87 records involving 83 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abilify Maintena by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Uzedy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $484.09 | 26.9% | 17 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $413.92 | 23.0% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $242.53 | 13.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $209.76 | 11.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $106.35 | 5.9% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $100.05 | 5.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $93.37 | 5.2% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $79.86 | 4.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $66.25 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,684.69 | 31 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $484.09 | 17 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $246.32 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $209.76 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $141.29 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $117.54 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $106.35 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $100.05 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.37 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $66.25 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $56.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UZEDY uzedy |
2025 | Uzedy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 87 supporting records · 83 recipient NPIs · example record 1225319985 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | UZEDY open payments reported associated product |
CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226 |
Uzedy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 80 |
| Clonazepam | Clonazepam | 256 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 36 |
| Metformin Hcl | Metformin Hcl | 214 | 35 |
| Trazodone Hcl | Trazodone Hcl | 213 | 37 |
| Omeprazole | Omeprazole | 209 | 43 |
| Lisinopril | Lisinopril | 208 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 38 |
| Gabapentin | Gabapentin | 185 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 50 |
| Buspirone Hcl | Buspirone Hcl | 138 | 23 |
| Lorazepam | Lorazepam | 138 | 23 |
| Alprazolam | Alprazolam | 128 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 115 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 113 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 20 |
| Aripiprazole | Aripiprazole | 101 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 93 | 14 |
| Tramadol Hcl | Tramadol Hcl | 93 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 17 |
| Mirtazapine | Mirtazapine | 79 | 15 |
| Jardiance | Empagliflozin | 78 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 14 |
| Topiramate | Topiramate | 71 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 20 |
| Famotidine | Famotidine | 69 | 11 |
| Lamotrigine | Lamotrigine | 69 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 65 | 16 |
| Losartan Potassium | Losartan Potassium | 64 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 64 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 13 |
| Olanzapine | Olanzapine | 62 | 14 |
| Trulicity | Dulaglutide | 62 | 11 |
| Bupropion Xl | Bupropion Hcl | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | suppressed |
| Diazepam | Diazepam | 57 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 57 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 55 | suppressed |
| Vraylar | Cariprazine Hcl | 55 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | suppressed |
| Rexulti | Brexpiprazole | 50 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | suppressed |
| Furosemide | Furosemide | 49 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | suppressed |
| Eliquis | Apixaban | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 41 | 12 |
| Potassium Chloride | Potassium Chloride | 41 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Perphenazine | Perphenazine | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 36 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Belsomra | Suvorexant | 34 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 11 |
| Clozapine | Clozapine | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 31 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 29 | 11 |
| Allopurinol | Allopurinol | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Abilify Maintena | Aripiprazole | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fetzima | Levomilnacipran Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Uzedy | Risperidone | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 11 | suppressed |
| Fanapt | Iloperidone | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,796.18 · 32 records | E.R. Squibb & Sons, L.L.C. | ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, BRIXADI, CAPVAXIVE, COBENFY, INVEGA SUSTENNA, LYBALVI, UZEDY, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Invega Sustenna play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error